NEW YORK (GenomeWeb News) – MDxHealth and Ghent University announced today that they have formed a new epigenetics research center to accelerate innovations in personalized medicine.
The partners have established NXTGNT, a Center in Pharmaco (Epi)genomics, at Ghent University within its laboratory of pharmaceutical biotechnology. The Center, which will be fully operational as of Dec. 1, will bring together disease-centered basic researchers, clinical validation teams, and bioinformaticians to apply epigenomics technology to personalized medicine.
The facility also will house researchers from MDxHealth, which is based in Irvine, Calif., and has its European headquarters in Liege, Belgium, who will develop epigenetic-based tests.
"There is a history of successful collaboration between MDxHealth and the University of Ghent, where much of the early epigenetics sequencing work on our biomarkers was conducted," MDxHealth CEO Jan Groen said in a statement. "We believe our experience in successfully developing personalized cancer epigenetic tests combined with the sequencing, bioinformatics, and methylome analysis expertise contained in the new Center will prove extremely attractive to the pharmaceutical industry."